The goal of the CRC 1160
The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.
The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.
News
Landesforschungspreis Baden-Württemberg für Angewandte Forschung for Scientist of CRC 1160
Feb 27, 2026 –
Prof. Dr. Robert Zeiser, principal investigator of CRC 1160 (B09, B10), has been awarded the Landesforschungspreis Baden-Württemberg für Angewandte Forschung for his pioneering work in cancer medicine.
Publications
Wöhrle S, Ćiković T, Dufossez C, Neuwirt E, Puma E, Kraatz F, Kostina A, Gorka O, Kreutz C, Groß CJ, Groß O. 2026. NEK7 accelerates NLRP3 inflammasome activation. J Mol Biol. Jul 29:169960. doi: 10.1016/j.jmb.2026.169960.
Oberhardt V, Degasperi E, Maas M, Borghi M, Heim K, Soffredini R, Anolli MP, Facchetti F, Narguet S, Asselah T, Alizei ES, Sogukpinar Ö, Winkler F, Llewellyn-Lacey S, Emmerich F, Price DA, Boettler T, Bengsch B, Luxenburger H, Hofmann M, Thimme R, Lampertico P, Neumann-Haefelin C. 2026. Fate of hepatitis D virus-specific CD8+ T cells during bulevirtide monotherapy in patients with chronic hepatitis delta☆. JHEP Rep. 2026 Jul 24:101970. doi: 10.1016/j.jhepr.2026.101970.
Chen Y, Ankerhold J, Jia T, Wolkewitz M, Fuchs J, Yuan L, Bai T, Groen K, Kuratli R, Hale BG, Kochs G, Wang D, Schwemmle M, Shu Y, Graf L. 2026. Autoantibodies against type I interferons in patients with zoonotic H7N9 influenza: an observational case-control study. EBioMedicine. 2026 Aug;130:106387. doi: 10.1016/j.ebiom.2026.106387.
Fliegauf M, Gamez-Diaz L, Mrovecova P, God CM, Geiger VF, Camacho-Ordonez N, Posadas-Cantera S, Murray C, Warnatz K, Keller B, Grimbacher B. 2026. A Detrimental NFKB2 Missense Variant is Associated with Hypogammaglobulinemia. J Clin Immunol. 2026 Jul 11;46(1):75. doi: 10.1007/s10875-026-02051-9.
Groß PR, Petersen S, Wang Z, Shamshiri B, de Maissin H, Lucas S, Gorka O, Heß L, Marco-Rius I, Mangas-Florencio L, Martins AF, Boehm-Sturm P, Zaitsev M, Zeiser R, Hövener JB, Reinheckel T, Groß O, Schmidt AB. 2026. Minute-Scale Repeated Metabolic Probing of Living Cells Enabled by Rapid Parahydrogen-Based Hyperpolarization. Angew Chem Int Ed Engl. 2026 Jul 10:e4855536. doi: 10.1002/anie.4855536.
Contact
Scientific Manager/Administration
Dr. Heike Ufheil
Institute for Immunodeficiency (IFI),
Center for Chronic Immunodeficiency (CCI)
Medical Center – University of Freiburg
